1-4 of 4
Kishan K Patel
Close
Sort by
Journal Articles

Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1 -Mutant Acute Myeloid Leukemia

Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A. Podoltsev, Maximilian F. Stahl, Jessica M. Stempel, Eytan Stein, Scott F. Huntington, Amer M. Zeidan
Journal: Blood
Blood (2022) 140 (Supplement 1): 319–321.
https://doi.org/10.1182/blood-2022-158465
Published: 2022
Journal Articles

Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia

Jan Philipp Bewersdorf, Kishan K. Patel, George Goshua, Rory M. Shallis, Nikolai A. Podoltsev, Scott F. Huntington, Amer M. Zeidan
Journal: Blood
Blood (2022) 139 (11): 1766–1770.
https://doi.org/10.1182/blood.2021014401
Published: 2022
Includes: Supplemental data
Journal Articles

Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to Conventional Cytarabine-Daunorubicin Chemotherapy in Acute Myeloid Leukemia

Jan Philipp Bewersdorf, George Goshua, Kishan K Patel, Rory M. Shallis, Nikolai Podoltsev, Scott F. Huntington, Amer M. Zeidan
Journal: Blood
Blood (2021) 138 (Supplement 1): 113.
https://doi.org/10.1182/blood-2021-144992
Published: 2021
Journal Articles

Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia

Clinical Trials & Observations
Kishan K. Patel, Iris Isufi, Shalin Kothari, Amy J. Davidoff, Cary P. Gross, Scott F. Huntington
Journal: Blood
Blood (2020) 136 (17): 1946–1955.
https://doi.org/10.1182/blood.2020004922
Published: 2020
Includes: Supplemental data